- Conditions
- Meibomian Gland Dysfunction
- Interventions
- Meibomian gland (MG) expression
- Procedure
- Lead sponsor
- University of the Incarnate Word
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pseudophakia
- Interventions
- Visual Acuity, Defocus Curve
- Diagnostic Test
- Lead sponsor
- Berkeley Eye Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myopia
- Interventions
- NeuroVision's NVC treatment for Low Myopia
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Meibomian Gland Dysfunction (MGD)
- Interventions
- Vevye(Cyclosporine 0.1% Ophthalmic Solution)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
- Interventions
- Gene Therapy product-MCO-010
- Biological
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
- Conditions
- Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
- Interventions
- No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
- Device · Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vestibular Hypofunction, Binocular Vision Abnormalities, Reduced Vision
- Interventions
- StableEyes: Incremental Vestibulo-Ocular Reflex Adaptation (IVA)
- Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Myopia, Astigmatism
- Interventions
- Visibly Vision Test
- Device
- Lead sponsor
- Visibly
- Industry
- Eligibility
- 22 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Harlingen, Texas
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
- Interventions
- Gene Therapy Product-MCO-010, Sham Injection
- Biological · Procedure
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
- Conditions
- Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
- Interventions
- Visual acuity (presenting and pinhole), Optical coherence tomography (OCT), Intraocular pressure, Active linkage to care, Fundus Photography
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 60,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Vestibular Schwannoma, Inner Ear Disease, Dizziness, Neurofibromatosis 2, Vestibular Disorder
- Interventions
- VOR precision training
- Behavioral
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 8 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Visual Acuity
- Interventions
- Blink® Tears eye drops, Investigational lipid eye drops
- Drug
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Saint Augustine, Florida
- Conditions
- Visual Acuity
- Interventions
- senofilcon A contact lenses made with a novel manufacturing technology, senofilcon A contact lenses made with the current manufacturing technology
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Orange Park, Florida • Tallahassee, Florida + 3 more
- Conditions
- Visual Impairment
- Interventions
- Non invasive visual acuity testing
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Retinopathy of Prematurity
- Interventions
- Investigational ultracompact OCT and OCTA system, retinal photographs
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Ptosis, Macular Degeneration, Ametropia
- Interventions
- Virtual Reality Headset
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Usher Syndrome, Type 2A, Retinitis Pigmentosa 39
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 9
- States / cities
- San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 6 more
- Conditions
- Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
- Interventions
- OPGx-RDH12
- Drug
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Visual Acuity
- Interventions
- Blink® Tears eye drops in a multidose bottle, Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
- Drug
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Maitland, Florida • Tyler, Texas
- Conditions
- Visual Acuity
- Interventions
- senofilcon A, Control
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Vestibular Disorder, Hearing Loss, Sensorineural
- Interventions
- Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity
- Behavioral
- Lead sponsor
- Father Flanagan's Boys' Home
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Degenerative Disc Disease
- Interventions
- Tranexamic Acid, Saline Solution, Visual Acuity Exam, 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
- Drug · Diagnostic Test
- Lead sponsor
- Catherine R. Olinger
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Inherited Retinal Degeneration, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Ataxia
- Interventions
- dantrolene sodium
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri